Has Smith Ho received payments from drug or device companies?

Yes. Drug and device makers reported $2,040 in general payments to Smith Ho across 94 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Smith Ho did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Smith Ho come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Smith Ho

Internal Medicine · Takoma Park, MDNPI 1265611230

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,474 and has fallen 91.5% since, to $125 in 2021.

$2,040in general payments, 2019–2025

Across 94 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$363
Gilead$250
Pfizer$179
Merck$160
Novartis$149
Esperion Therapeutics, Inc.$125
plus $813 from 18 others

What the payments were for

Food & beverage$2,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	35	$363
Gilead	2	$250
Pfizer	5	$179
Merck	6	$160
Novartis	2	$149
Esperion Therapeutics, Inc.	1	$125
GSK	1	$125
Arbor Pharmaceuticals, Inc.	8	$111
Johnson & Johnson	1	$91
Takeda Pharmaceuticals U.S.A., Inc.	7	$87
Corcept Therapeutics	5	$80
AstraZeneca	4	$57
Amarin Pharma, Inc.	3	$46
Kowa Pharmaceuticals America, Inc.	2	$31
Boehringer Ingelheim	2	$28
Amgen	2	$27
Lilly USA, LLC	1	$20
E.r. Squibb & Sons, L.L.C.	1	$19
Antares Pharma, Inc.	1	$18
Scilex Pharmaceuticals Inc.	1	$17
AbbVie	1	$16
Phadia US Inc.	1	$14
Grifols USA, LLC	1	$13
Sanofi Pasteur Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,040 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland →

Other internal medicine in Takoma Park

Marianne MannHighland$2.1M
Param DedhiaBaltimore$636K
Curtis RosebraughAshton$418K
Mark CorriereColumbia$402K
Gregory PokrywkaTowson$377K
Shawn DhillonBaltimore$227K
Brian HarveyAnnapolis$220K
Jeremy SugarmanBaltimore$210K
Florence HounPotomac$161K
Matthew MintzBethesda$135K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →